Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877751 | 0.89 | PIK3CA (0.50) | MALT1PIK3CAMTORMAP3K12 | |
| SCHEMBL3887144 | 0.89 | PIK3CA (0.50) | PIK3CAMTORMAP3K12 | |
| SCHEMBL3877301 | 0.87 | PIK3CA (0.48) | PIK3CAMTORMAP3K12KDM4EL3MBTL1 | |
| SCHEMBL3879387 | 0.87 | PIK3CA (0.49) | MALT1PIK3CALRRK2MTORMAP3K12 | |
| SCHEMBL3888444 | 0.85 | TRPV1 (0.49) | PIK3CAMTORMAP3K12 | |
| SCHEMBL3878644 | 0.85 | TRPV1 (0.49) | PIK3CAMTORMAP3K12 | |
| SCHEMBL4151864 | 0.84 | MTOR (0.46) | PIK3CAMTORMAP3K12KDM4EL3MBTL1 | |
| SCHEMBL907686 | 0.84 | MTOR (0.47) | PIK3CAMTORMAP3K12 | |
| SCHEMBL3884319 | 0.84 | PIK3CA (0.52) | MALT1PIK3CAMTORMAP3K12KDM4E | |
| SCHEMBL13761444 | 0.83 | MALT1 (0.47) | MALT1DRD2HTR2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MALT1 1393/4885PIK3CA 1107/4885LRRK2 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.